Q-omics provides the consensus-scored NDUFAF2 profile across patient tissues and cancer cell-line models. NDUFAF2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, NDUFAF2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, NDUFAF2 RNA expression shows 17,921 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SCLC, KIRC, and UVM as cancer lineages where NDUFAF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFAF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFAF2 survival associations across molecular data types. NDUFAF2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFAF2 RNA expression–survival associations across cancer types. High NDUFAF2 expression shows unfavorable associations in SCLC, KICH, LIHC, KIRP, UCS and UCEC. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for NDUFAF2 RNA expression.
This table summarizes NDUFAF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFAF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFAF2 shows lower tumor expression in BRCA and higher tumor expression in KIRC, LIHC, COAD, LUAD and CHOL. The KIRC box plot shows higher NDUFAF2 RNA expression in tumor versus normal tissue (log2 FC = +0.527, t-test p < 0.001).
This table shows molecular features associated with NDUFAF2 in patient tissues and cancer cell lines. In patient samples, NDUFAF2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFAF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
